Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,460 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial.
Mesa RA, Schaap N, Vannucchi AM, Kiladjian JJ, Passamonti F, Zweegman S, Talpaz M, Verstovsek S, Rose S, Abraham P, Lord-Bessen J, Tang D, Guo S, Ye X, Harrison CN. Mesa RA, et al. Among authors: abraham p. Hemasphere. 2021 Apr 29;5(5):e553. doi: 10.1097/HS9.0000000000000553. eCollection 2021 May. Hemasphere. 2021. PMID: 33969273 Free PMC article.
Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial.
Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Jourdan E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Verstovsek S, Tang D, Abraham P, Lord-Bessen J, Rose S, Guo S, Liao W, Mesa RA. Harrison CN, et al. Among authors: abraham p. Hemasphere. 2021 Apr 29;5(5):e562. doi: 10.1097/HS9.0000000000000562. eCollection 2021 May. Hemasphere. 2021. PMID: 33969275 Free PMC article.
Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes.
Mascarenhas J, Harrison C, Schuler TA, Liassou D, Garretson M, Miller TA, Mahadevan S, McBride A, Tang D, DeGutis IS, Abraham P, Kish J, Feinberg BA, Gerds AT. Mascarenhas J, et al. Among authors: abraham p. Clin Lymphoma Myeloma Leuk. 2024 Feb;24(2):122-132. doi: 10.1016/j.clml.2023.09.008. Epub 2023 Sep 29. Clin Lymphoma Myeloma Leuk. 2024. PMID: 37839939 Free article.
Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer.
Le DT, Ott PA, Korytowsky B, Le H, Le TK, Zhang Y, Maglinte GA, Abraham P, Patel D, Shangguan T, Chau I. Le DT, et al. Among authors: abraham p. Clin Colorectal Cancer. 2020 Mar;19(1):32-38.e3. doi: 10.1016/j.clcc.2019.09.001. Epub 2019 Sep 24. Clin Colorectal Cancer. 2020. PMID: 31813769 Free article.
A Comparison of Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving First-Line Therapy for Unresectable Advanced Gastric or Gastroesophageal Junction Cancer Versus Esophageal Adenocarcinomas.
Shankaran V, Xiao H, Bertwistle D, Zhang Y, You M, Abraham P, Chau I. Shankaran V, et al. Among authors: abraham p. Adv Ther. 2021 Jan;38(1):707-720. doi: 10.1007/s12325-020-01567-9. Epub 2020 Nov 26. Adv Ther. 2021. PMID: 33244736 Free PMC article.
1,460 results